Are you a Healthcare Professional?
The content in our Healthcare Professionals section can only legally be viewed by people working in the healthcare industry.
Please login to access product support, patient information and training materials.
If you are a patient seeking medical advice, please see your healthcare professional.
The Atmo Gas Capsule System measures whole gut and regional gut (stomach, small bowel, and colon) transit times. Measurements of gastrointestinal tract transit times are used for evaluating motility disorders such as gastroparesis and slow transit constipation.
The Atmo Gas Capsule System is an investigational device exclusively for use in clinical investigations. The Atmo Gas Capsule System is pending FDA 510(k) clearance and is not available for sale.
Image for illustration purposes only. Actual product may differ in appearance.
More than 40% of people worldwide are expected to suffer from a functional gut disorder1, affecting quality of life and healthcare use. Functional gut disorders are challenging to manage and a third of patients are expected to remain undiagnosed or suffer from recurrence.
These disorders are characterized by chronic symptoms such as abdominal pain, dysphagia, dyspepsia, diarrhea, constipation and bloating. This condition is caused by disorders of gastrointestinal (GI) function, including dysmotility.
Motility refers to the rate that food contents move through the regions of the gut. Delayed gastric emptying and slow transit constipation are dysmotility conditions. The Atmo Capsule uses data from gas sensors and other onboard sensors to determine its location in the gastrointestinal tract to measure gut motility.
1. Sperber et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study, Gastroenterology, 2021
The Atmo Gas Capsule is an ingestible capsule that measures gases directly at the source of production in the gastrointestinal tract (GI tract) and transmits the data wirelessly.
The Atmo Gas Capsule System measures whole gut and regional gut (stomach, small bowel, and colon) transit times. Measurements of gastrointestinal tract transit times are used for evaluating motility disorders such as gastroparesis and slow transit constipation.
Transit times are derived from measures of temperature, hydrogen concentration, carbon dioxide concentration, along with indicators of oxygen level, capsule tumble, and antenna reflectance.
The Capsule can electronically report important data from these measures and wirelessly transmits the data which can be uploaded to the Cloud for aggregation, analysis and patient reporting.
April 15, 2025. Atmo Biosciences today announced the successful assignment of its foundational patent portfolio from RMIT University. Under this agreement, RMIT has transferred all patents and associa...
March 4, 2025. Today, Atmo Biosciences announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology. The study validates the Atmo Capsule for assessing whole an...
14 October 2024. Atmo Biosciences is pleased to announce that it has been awarded funding through the ANDHealth+ Stage 2 Commercialization Program, aimed at helping five digital health companies scale...
May 2, 2024. Clinical Research. Atmo Biosciences’ ingestible gas-sensing capsule was used to assess the impact of an early-time restricted eating diet on gastrointestinal hydrogen production and gas...
April 9, 2024. Atmo Biosciences is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study to assess whole and regional gut transit time in subjects with...
December 14, 2023. Atmo Biosciences has reached its patient recruitment target ahead of schedule for its dysmotility pivotal clinical study. More than 200 patients were recruited in a multi-site clini...
AUSBIZ
The tiny device revolutionising gut health diagnostics
24 September 2021
AUSTRALIAN FINANCIAL REVIEW
Gut health medtech Atmo Biosciences raises $9.6m
23 September 2021
BBC
Gas detecting pill could diagnose poor gut health
23 January 2018
David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology.
Houston Methodist Hospital
Chief of Gastroenterology and Hepatology.
University of Michigan
Distinguished University Chair in Gastroenterology & Professor of Medicine. Director, Neurogastroenterology/Motility and Digestive Health Clinical Research Center.
Augusta University
Professor of Medicine, Vice-Chief of the Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine.
David Geffen School of Medicine at UCLA
Director of Research for Digestive Disease & Surgery Institute.
Cleveland Clinic
Director of Center for Neurointestinal Health at Massachusetts General Hospital and Associate Professor at Harvard Medical School.
President & CEO, Co-Founder
Chair of the Board & Non-Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director
Head of Clinical Affairs & Co-Founder
Head of Research and Development/Product Development & Co-Founder
Chief Financial Officer & Company Secretary
Chief Operating Officer
Head of Commercial
Manufacturing Manager
Lead Scientific Advisor
